Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CARM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CARM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CARM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CARM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
GO:0071383110 | Esophagus | ESCC | cellular response to steroid hormone stimulus | 127/8552 | 204/18723 | 1.26e-06 | 1.55e-05 | 127 |
GO:003051819 | Esophagus | ESCC | intracellular steroid hormone receptor signaling pathway | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
GO:004340119 | Esophagus | ESCC | steroid hormone mediated signaling pathway | 87/8552 | 136/18723 | 1.25e-05 | 1.15e-04 | 87 |
GO:00165718 | Esophagus | ESCC | histone methylation | 89/8552 | 141/18723 | 2.17e-05 | 1.87e-04 | 89 |
GO:00454449 | Esophagus | ESCC | fat cell differentiation | 135/8552 | 229/18723 | 3.38e-05 | 2.78e-04 | 135 |
GO:00456007 | Esophagus | ESCC | positive regulation of fat cell differentiation | 46/8552 | 66/18723 | 6.72e-05 | 5.11e-04 | 46 |
GO:19052142 | Esophagus | ESCC | regulation of RNA binding | 12/8552 | 12/18723 | 8.21e-05 | 6.01e-04 | 12 |
GO:00331438 | Esophagus | ESCC | regulation of intracellular steroid hormone receptor signaling pathway | 50/8552 | 74/18723 | 1.16e-04 | 8.04e-04 | 50 |
GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
GO:000975516 | Esophagus | ESCC | hormone-mediated signaling pathway | 106/8552 | 190/18723 | 3.13e-03 | 1.30e-02 | 106 |
GO:003052014 | Esophagus | ESCC | intracellular estrogen receptor signaling pathway | 35/8552 | 54/18723 | 3.55e-03 | 1.45e-02 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CARM1 | SNV | Missense_Mutation | rs139191688 | c.1721N>T | p.Thr574Met | p.T574M | Q86X55 | protein_coding | deleterious_low_confidence(0.01) | benign(0.374) | TCGA-CV-7242-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | novel | c.422N>T | p.Thr141Met | p.T141M | Q86X55 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CV-7413-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1665N>A | p.Met555Ile | p.M555I | Q86X55 | protein_coding | deleterious_low_confidence(0.03) | benign(0.023) | TCGA-CV-A45Q-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | deletion | Frame_Shift_Del | | c.450delN | p.Gln151SerfsTer12 | p.Q151Sfs*12 | Q86X55 | protein_coding | | | TCGA-CN-6995-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | novel | c.800G>A | p.Arg267His | p.R267H | Q86X55 | protein_coding | deleterious(0) | possibly_damaging(0.591) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
CARM1 | SNV | Missense_Mutation | novel | c.1546A>G | p.Thr516Ala | p.T516A | Q86X55 | protein_coding | tolerated_low_confidence(0.37) | benign(0) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
CARM1 | SNV | Missense_Mutation | rs753002802 | c.1819G>A | p.Gly607Arg | p.G607R | Q86X55 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.666) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1675N>G | p.Ile559Val | p.I559V | Q86X55 | protein_coding | tolerated_low_confidence(0.06) | benign(0.024) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
CARM1 | SNV | Missense_Mutation | novel | c.1211N>G | p.Leu404Arg | p.L404R | Q86X55 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
CARM1 | SNV | Missense_Mutation | rs527617157 | c.695C>T | p.Thr232Met | p.T232M | Q86X55 | protein_coding | tolerated(0.09) | possibly_damaging(0.637) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 336446915 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | | EOSIN | EOSIN | 18348515 |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 178103610 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 310264736 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 315661334 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 178103609 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 315661333 | BIIB021 | |